Design Therapeutics, Inc. (NasdaqGS: DSGN)
Health Care · Biotechnology · US
$11.65
+1.39% today · +63.6% 1Y
Design Therapeutics, Inc. (NasdaqGS: DSGN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $729.08M and employs 55 people.
Over the last twelve months the share price has gained 63.6%, trading between 5.28 and 17.25.
Tweenvest scores Design Therapeutics, Inc. across four factors: quality 38/100, value 69/100. Its strongest factor is value.
DSGN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $729.08M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.18
- Dividend yield
- —
- Beta (5Y)
- 1.69
- 52-week high
- $17.25
- 52-week low
- $5.28
- Avg volume (3M)
- —
- Shares outstanding
- 62.58M
- Employees
- 55
- Next earnings
- —
About Design Therapeutics, Inc.
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
- ISIN
- US25056L1035
- Founded
- 2017
- Listed since
- Mar 29, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| HanchorBio Inc.TWSE: 7827 | $739.81M | NT$169.00 | +1.20% |
| Solid Biosciences Inc.NasdaqGS: SLDB | $736.64M | $6.87 | +0.29% |
| 4D Molecular Therapeutics, Inc.NasdaqGS: FDMT | $736.41M | $13.33 | +4.96% |
| Avalo Therapeutics, Inc.NasdaqCM: AVTX | $732.05M | $13.65 | +1.64% |
| ChemPartner PharmaTech Co.,Ltd.SZSE: 300149 | $713.97M | CN¥9.47 | -4.34% |
| Prime Medicine, Inc.NasdaqGM: PRME | $709.84M | $3.99 | +11.45% |
| Pharming Group N.V.ENXTAM: PHARM | $694.55M | €0.88 | +3.72% |
| Kexing Biopharm Co., Ltd.SHSE: 688136 | $689.04M | CN¥23.24 | -4.24% |
Figures last refreshed Oct 11, 2026.